

EXHIBIT A

(12) **United States Patent**
Lulla et al.

(10) **Patent No.:** **US 8,163,723 B2**
(45) **Date of Patent:** **Apr. 24, 2012**

(54) **COMBINATION OF AZELASTINE AND STEROIDS**

(75) Inventors: **Amar Lulla**, Mumbai (IN); **Geena Malhotra**, Mumbai (IN)

(73) Assignee: **CIPLA Limited**, Mumbai (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 77 days.

(21) Appl. No.: **12/879,515**

(22) Filed: **Sep. 10, 2010**

(65) **Prior Publication Data**
US 2010/0331289 A1 Dec. 30, 2010

Related U.S. Application Data

(62) Division of application No. 10/518,016, filed as application No. PCT/GB03/02557 on Jun. 13, 2003.

(30) **Foreign Application Priority Data**
Jun. 14, 2002 (GB) 0213739.6

(51) **Int. Cl.**
A61K 31/55 (2006.01)

(52) **U.S. Cl.** **514/171**

(58) **Field of Classification Search** None
See application file for complete search history.

4,607,028 A	8/1986	Schmidlin
4,710,495 A	12/1987	Bodor
4,861,765 A	8/1989	Mitsukuchi et al.
4,992,474 A	2/1991	Skidmore et al.
4,994,439 A	2/1991	Longnecker et al.
4,996,335 A	2/1991	Bodor
5,063,222 A	11/1991	Komoto et al.
5,081,113 A	1/1992	Claussner et al.
5,164,194 A	11/1992	Hettche
5,202,316 A	4/1993	Claussner et al.
5,232,919 A	8/1993	Scheffler et al.
5,271,946 A	12/1993	Hettche
5,362,721 A	11/1994	Stache et al.
5,420,120 A	5/1995	Boltralik
5,608,093 A	3/1997	Stache et al.
5,658,549 A	8/1997	Akehurst et al.
5,658,919 A	8/1997	Ratnaraj et al.
5,707,984 A	1/1998	Tjoeng et al.
5,837,699 A	11/1998	Sequeira et al.
5,849,265 A	12/1998	Li-Bovet et al.
5,889,015 A	3/1999	Sequeira et al.
5,914,122 A	6/1999	Otterbeck et al.
5,972,920 A	10/1999	Seidel
5,981,517 A	11/1999	Bodor
6,017,963 A	1/2000	Alfonso et al.
6,057,307 A	5/2000	Sequeira et al.
6,127,353 A	10/2000	Yuen et al.
6,136,294 A	10/2000	Adjei et al.
6,197,761 B1	3/2001	Biggadike et al.
6,261,539 B1	7/2001	Adjei et al.
6,294,153 B1	9/2001	Modi
6,319,513 B1	11/2001	Dobrozi
6,330,938 B1	12/2001	Herve et al.
6,391,340 B1	5/2002	Malmqvist-Granlund et al.
6,395,300 B1	5/2002	Straub et al.
6,416,743 B1	7/2002	Fassberg et al.
6,525,228 B2	2/2003	Chauvin et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2003244799 B2 12/2003

(Continued)

OTHER PUBLICATIONS

Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No. 12/508,388, filed Jul. 23, 2009.

(Continued)

Primary Examiner — Johann Richter
Assistant Examiner — Thor Nielsen
(74) *Attorney, Agent, or Firm* — Conley Rose, P.C.; Rodney B. Carroll

(57) **ABSTRACT**

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

28 Claims, No Drawings

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,837,464 A	6/1958	Nobile
3,067,197 A	12/1962	Agnello et al.
3,312,590 A	4/1967	Elks et al.
3,506,694 A	4/1970	Oxley
3,557,162 A	1/1971	Voorschoten et al.
3,639,434 A	2/1972	Oxley et al.
3,755,302 A	8/1973	Ercoli et al.
3,828,080 A	8/1974	May et al.
3,856,828 A	12/1974	Phillipps et al.
3,891,631 A	6/1975	Phillipps et al.
3,981,894 A	9/1976	Phillipps et al.
3,989,686 A	11/1976	Phillipps et al.
4,093,721 A	6/1978	Phillipps et al.
4,113,680 A	9/1978	Kamano et al.
4,187,301 A	2/1980	Edwards
4,188,385 A	2/1980	Edwards
4,198,403 A	4/1980	Alvarez
4,221,787 A	9/1980	Bodor et al.
4,261,984 A	4/1981	Alvarez
4,263,289 A	4/1981	Edwards
4,267,173 A	5/1981	Draper
4,285,937 A	8/1981	Kalvoda
4,310,466 A	1/1982	Edwards
4,335,121 A	6/1982	Phillipps et al.
4,377,575 A	3/1983	Stache et al.
4,472,393 A	9/1984	Shapiro

US 8,163,723 B2

Page 2

U.S. PATENT DOCUMENTS

6,537,983 B1 3/2003 Biggadike et al.
 6,583,180 B2 6/2003 Link et al.
 6,787,532 B2 9/2004 Biggadike et al.
 6,921,757 B2 7/2005 Cuenoud et al.
 7,101,866 B2 9/2006 Biggadike et al.
 7,244,742 B2 7/2007 Pieper et al.
 7,776,315 B2 8/2010 Pairet et al.
 2002/0061281 A1 5/2002 Osbakken et al.
 2002/0076382 A1 6/2002 Kaplan et al.
 2002/0081266 A1 6/2002 Woolfe et al.
 2002/0103392 A1 8/2002 Stache et al.
 2002/0165211 A1 11/2002 Biggadike et al.
 2002/0173496 A1 11/2002 Biggadike
 2002/0177581 A1 11/2002 Biggadike
 2003/0018019 A1 1/2003 Meade et al.
 2003/0073676 A1 4/2003 Biggadike et al.
 2003/0109511 A1 6/2003 Biggadike et al.
 2003/0144257 A1 7/2003 Biggadike et al.
 2003/0158163 A1 8/2003 Cuenoud et al.
 2004/0053904 A1 3/2004 Komoto et al.
 2004/0136918 A1 7/2004 Garrett et al.
 2004/0204399 A1 10/2004 Osbakken et al.
 2004/0235807 A1 11/2004 Weinrich et al.
 2004/0242638 A1 12/2004 Yanni et al.
 2005/0163724 A1 7/2005 Miyadia et al.
 2005/0192261 A1 9/2005 Jost-Price et al.
 2006/0025391 A1 2/2006 Lulla et al.
 2006/0110331 A1 5/2006 Dang et al.
 2006/0228306 A1 10/2006 Lane
 2007/0020330 A1 1/2007 Dang et al.
 2009/0286762 A1 11/2009 Myles et al.
 2009/0291143 A1 11/2009 Lulla et al.
 2009/0318397 A1 12/2009 Lulla et al.
 2010/0152147 A1 6/2010 Fuge et al.

FOREIGN PATENT DOCUMENTS

BE 889563 A 11/1981
 DE 1059906 6/1959
 DE 3836579 A1 5/1989
 DE 19947234 A1 9/1999
 DE 10152369 A1 5/2002
 EP 0004773 10/1979
 EP 0057401 8/1982
 EP 0179583 4/1986
 EP 0393658 10/1990
 EP 0416951 3/1991
 EP 0780127 6/1997
 EP 0780127 A1 6/1997
 EP 1519731 B1 4/2009
 EP 2072051 A1 6/2009
 GB 1191965 5/1970
 GB 1296458 11/1972
 GB 1384372 2/1975
 GB 1438940 6/1976
 GB 1517278 7/1978
 GB 2079755 1/1982
 GB 2088877 6/1982
 GB 2140800 12/1984
 GB 2389530 A 12/2003
 IL 109656 2/1998
 JP 04208267 7/1992
 JP 8291072 11/1996
 JP 8291073 11/1996
 JP 2002-053485 2/2002
 WO 8903390 4/1989
 WO 9015816 12/1990
 WO 9104252 4/1991
 WO 9214472 9/1992
 WO 9531964 11/1995
 WO 9619199 6/1996
 WO 9632151 10/1996
 WO 9701337 A1 1/1997
 WO 9705136 2/1997
 WO 9715298 5/1997
 WO 9721721 6/1997

WO 9740836 11/1997
 WO 9746243 A1 12/1997
 WO 9817676 4/1998
 WO 9834596 8/1998
 WO 9848839 A1 11/1998
 WO 9901467 1/1999
 WO 9925359 5/1999
 WO 9932089 7/1999
 WO 0016814 3/2000
 WO 0033892 6/2000
 WO 0038811 7/2000
 WO 0048587 8/2000
 WO 0049993 8/2000
 WO 0066522 11/2000
 WO 0104118 1/2001
 WO 0120331 3/2001
 WO 0154481 8/2001
 WO 0154664 8/2001
 WO 0157025 8/2001
 WO 0162722 8/2001
 WO 0178736 10/2001
 WO 0178739 10/2001
 WO 0178741 10/2001
 WO 0178745 10/2001
 WO 0200199 1/2002
 WO 0200679 1/2002
 WO 0202565 1/2002
 WO 0207767 1/2002
 WO 0208243 1/2002
 WO 0212265 2/2002
 WO 0212266 2/2002
 WO 0213868 2/2002
 WO 0226723 4/2002
 WO 0236106 5/2002
 WO 02051422 7/2002
 WO 02053186 7/2002
 WO 02066422 8/2002
 WO 02070490 9/2002
 WO 02076933 10/2002
 WO 02085296 10/2002
 WO 02088167 11/2002
 WO 02100879 12/2002
 WO 03000241 1/2003
 WO 03013427 2/2003
 WO 03033000 4/2003
 WO 03035668 5/2003
 WO 03040691 5/2003
 WO 03042229 5/2003
 WO 03042230 5/2003
 WO 03048181 6/2003
 WO 03062259 7/2003
 WO 03064445 8/2003
 WO 03066033 8/2003
 WO 03066036 8/2003
 WO 03066656 8/2003
 WO 03072592 9/2003
 WO 03086399 10/2003
 WO 03105856 A1 12/2003
 WO 2004013156 2/2004
 WO 2004019955 A1 3/2004
 WO 2008012338 A2 1/2008
 ZA 872389 4/1987

OTHER PUBLICATIONS

Office Action (Final) dated Feb. 24, 2011 (20 pages), U.S. Appl. No. 12/508,393, filed Jul. 23, 2009.
 Office Action dated Feb. 16, 2011, (22 pages), U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
 Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,388, filed Jul. 23, 2009, 22 pages.
 Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,393, filed Jul. 23, 2009, 31 pages.
 Schmidt, M. W., "The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis," *Journal of Clinical Pharmacology*, 1999, vol. 39, pp. 1062-1069.

US 8,163,723 B2

Page 3

- Nielsen, et al., "Intranasal corticosteroids for allergic rhinitis: superior relief?" *Drugs*, 2001, vol. 61, No. 11, pp. 1535-1691.
- Opponent's R116 Submission for EP1519731, 2011.
- CIPLA's response to Statement of Opposition for EP1519731, 2011.
- Shenfield, "Fixed drug combinations: which ones can be recommended?" *Current Therapeutics*, 1986, pp. 15-29.
- Opponent's Statement of Opposition for EP1519731, 2011.
- Result of oral proceedings dated Oct. 12, 2011 of EP Patent No. 1519731.
- Opponent's submission dated Oct. 6, 2011 to EP Patent No. 1519731.
- Patentee's submission dated Oct. 5, 2011 to EP Patent No. 1519731.
- Patentee's submission dated Sep. 29, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731.
- Opponent's submission dated Sep. 23, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731.
- Opponent's submission dated Sep. 23, 2011 regarding additional documents on EP Patent No. 1519731.
- Patentee's submission dated Sep. 19, 2011 on EP Patent No. 1519731.
- Patentee's response of Sep. 6, 2010 of EP Patent No. 1519731.
- Hampel, Frank C., et al., Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device, *Annals of Allergy, Asthma & Immunology*, Aug. 2010, vol. 105, pp. 168-173.
- Biggadike, Keith, Letter to the Editor, "Fluticasone furoate/fluticasone propionate—different drugs with different properties," *The Clinical Respiratory Journal*, 2011, pp. 183-184.
- Rapid response report: summary with critical appraisal, fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness, Jun. 13, 2011, Fluticasone Furoate for Seasonal Allergic Rhinitis.
- Office Action dated Sep. 9, 2011 of U.S. Appl. No. 12/508,388, filed Jul. 23, 2009.
- Office Action dated Sep. 15, 2011 of U.S. Appl. No. 12/508,393, filed Jul. 23, 2009.
- Search Report dated May 12, 2009 of EP 09075101.
- Search Report dated May 12, 2009 of EP 09075100.
- Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis anti-allergy/antiasthmatic," *Drugs of the Future*, Prous Science, ES, vol. 26, No. 11, Nov. 2001, pp. 1033-1039.
- Office Action dated Jul. 11, 2011—20632 IL.
- Office Action dated Aug. 31, 2010 (6 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Applicants' response dated Oct. 6, 2010 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Applicants' response dated Feb. 24, (2010) 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Office Action (Final) dated May 3, 2011 (8 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Applicants' response dated Jun. 22, 2011 (9 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Notice of Non-responsive Amendment dated Jul. 6, 2011 (3 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Applicants' response dated Sep. 6, 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
- Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," *J Allergy Clin Immunol*, vol. 103, No. 3, Part 2, pp. S386-S387, 1999.
- Duonase Data Sheet, "The complete rhinitis control," 6 pages, Cipla Limited, Mumbai, India, 2004.
- Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-SPEC-02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
- Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
- File history of Brazilian Patent Application No. PI 0312128-3, 27 pages, Apr. 2011.
- File history of Canadian Patent Application No. 2,489,427, 19 pages, Dec. 2010.
- File history of Polish Patent Application No. P-373001, 95 pages, May 2011.
- Notice of Allowance dated Oct. 3, 2011 (33 pages) in U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
- Salib, et al.; "Safety and Tolerability Profiles of Intranasal Antihistaminase and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis;" *Drug Safety*; 2003; vol. 26, No. 12, pp. 829-911.
- Office Action dated Apr. 7, 2011 (3 pages) from counterpart application, AU2009243420.
- Product Information, Nasonex®, Aug. 2001, 22 pages, Schering Corporation, Kenilworth, NJ, US.
- Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-SPEC-02/09.RS, 2 pages, FMC BioPolymer.
- Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC-02/09.RS, 2 pages, FMC BioPolymer.
- Ratner, Paul H., et al., "Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis," *Annals of Allergy, Asthma & Immunology*, Jan. 2008, vol. 100, Cover page, publishing page, pp. 74-81.
- Ratner, Paul H., et al., "A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis," *The Journal of Family Practice*, Aug. 1998, vol. 47, No. 2, pp. 118-125, Appleton & Lange.
- Reddy, Indra K., ed., "Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach," 1996, pp. 382-385 plus cover page and publication page, Technomic Publishing Company, Inc.
- Safety Data Sheet, SDS No. 110556, Jul. 4, 2008, V14, Flonase Nasal Spray, 5 pages, GlaxoSmithKline.
- Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, V13, Beconase Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
- Salib Rami Jean, et al., "Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis," *Drug Safety* 2003, vol. 26, No. 12, Cover page, publication page, pp. 863-893, ADIS Data Information BV.
- Simpson, Richard J., "Budesonide and terfenadine, separately and in combination, in the treatment of hay fever," *Annals of Allergy*, Dec. 1994, vol. 73, Cover page, publication page, pp. 497-502.
- Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," *J Allergy Clin Immunol*, 1999, vol. 103, No. 3, Part 2, pp. S386-S387, Mosby, Inc..
- Wang, De-Yun, "Treatment of Allergic Rhinitis: H1-Antihistamines and Intranasal Steroids," *Current Drug Targets—Inflammation & Allergy*, 2002, vol. 1, pp. 215-220, Bentham Science Publishers Ltd.
- Wiseman, Lynda R., et al., "Intranasal Fluticasone Propionate: A Reappraisal of its Pharmacology and Clinical Efficacy in the Treatment of Rhinitis," *Drugs*, 1997, vol. 53, No. 5, pp. 885-907, Adis International Limited.
- World Review 2001: The Pharmaceutical Market, vol. 1 International, IMC Health, 2001, cover, preface, and copyright pages plus pp. 4-42 and 5-1 through 5-11, IMS A.G.
- Applicant Response to foreign communication EP Patent 1519731, Aug. 11, 2011, 252 pages.
- "Azelastine," STN Registry No. 58581-89-8, STN Registry File, Retrieved Nov. 23, 2010, p. 1.
- "Fluticasone Furoate," STN Registry No. 397864-44-7, STN Registry File, Retrieved Nov. 23, 2010, p. 1.
- Astepro (azelastine HCl) Nasal Spray 0.15%, Meda Pharmaceuticals Inc., 2009, Press Release, pp. 1-4.
- Aigbirhio, Franklin I., et al., "Automated radiosynthesis of no-carrier-added [S-fluoromethyl-18F]Fluticasone propionate as a radiotracer for lung deposition studies with PET," *Journal of Labelled Compounds and Radiopharmaceuticals*, vol. 39, No. 7, 1997, pp. 569-584.
- Austin, et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," *Eur. Respir. J.*, 2002, vol. 20, pp. 1386-1392.
- Banov, et al., "Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis," *Annals of Allergy*, 1994, vol. 73, pp. 240-246.
- Baumgarten, C., et al., "Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone

US 8,163,723 B2

Page 4

- Berstein, et al., "Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis," *Clin. Exp. Allergy*, 2004, vol. 34, pp. 952-957.
- Brooks, et al., "Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination," *American Journal of Rhinology*, 1996, vol. 10, No. 3, pp. 193-199.
- Bryson, et al., "Intranasal fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis," *Drugs*, 1992, vol. 43, No. 5, pp. 760-775.
- Busse, William, et al., "Steroid-sparing effects of fluticasone propionate 100µg and salmeterol 50 µg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 µg administered twice daily," *J. Allergy Clin. Immunol.*, vol. 111, No. 1, Jan. 2003, pp. 57-65.
CAS Registry No. 102113-40-6, 2004.
- CAS Registry No. 90566-53-3, "Fluticasone," Nov. 16, 1984.
- Chapman, et al., "Anti-inflammatory activity of inhaled mometasone furoate in allergic mice," *Arzneimittelforschung ("Drug Research")*, 1998, vol. 48, No. 4, pp. 384-391.
- Daley-Yates, et al., "Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations," *Br. J. Clin. Pharmacol.*, 2001, vol. 51, pp. 103-105.
- Derby, et al., "Risk of cataract among users of intranasal corticosteroids," *J. Allergy Clin. Immunol.*, 2000, vol. 105, No. 5, pp. 912-916.
- Dewester, et al., "The efficacy of intranasal fluticasone propionate in relief of ocular symptoms associated with seasonal rhinitis," *Allergy and Asthma Proc.*, 2003, vol. 24, No. 5, pp. 331-337.
- Dictionary of Organic Compounds, 6th Ed., vol. 1, p. 3234, definition of "fluticasone," Chapman & Hall, 1996.
- Dolovich, et al., "Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis," *Annals of Allergy*, 1994, vol. 73, No. 2, pp. 147-153.
- Fowler, Stephen J., et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone," *J. Allergy Clin. Immunol.*, vol. 109, No. 6, Jun. 2002, pp. 929-935.
- Garner, R. C., et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of ¹⁴C-labelled drugs in plasma, urine and faecal extracts," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 24, 2000, pp. 197-209.
- Gawchik, et al., "Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis," *Am. J. Man. Care*, 1997, vol. 3, No. 7, pp. 1052-1058.
- Harding, "The human pharmacology of fluticasone propionate," *Respiratory Medicine*, 1990, vol. 84, Suppl. A, pp. 25-29.
- Howland, "Fluticasone propionate: topical or systemic effects?" *Clinical and Experimental Allergy*, 1996, vol. 26, Suppl. 3, pp. 18-22.
- Isogai, et al., "Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue," *J. Steroid Biochem. Mol. Biol.*, 1993, vol. 44, pp. 141-145.
- Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma," *Clin. Drug Invest.*, vol. 21, No. 9, 2001, pp. 633-642, 11 pages.
- Juniper, Elizabeth F., et al., "Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma," *Am. J. Respir. Med.*, vol. 1, No. 6, 2002, pp. 435-440.
- Kenley, Richard A., et al., "An automated, column-switching HPLC method for analyzing active and excipient materials in both cream and ointment formulations," *Drug Development and Industrial Pharmacy*, vol. 11 (9 & 10), 1985, pp. 1781-1796.
- Kertesz, Denis J., et al., "Thiol esters from steroid 17β-carboxylic acids: carboxylate activation and internal participation by 17 α-acylates," *J. Org. Chem.*, vol. 51, 1986, 14 pages.
- Kooreman, et al., "The synthesis of 17-esters of corticosteroids pro-
- Laforce, et al., "Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents," *J. Fam. Pract.*, 1994, vol. 38, No. 2, pp. 145-152.
- Lane, S. J., et al., "Evaluation of a new capillary electrochromatography/mass spectrometry interface using short columns and high field strengths for rapid and efficient analyses," *Rapid Communications in Mass Spectrometry*, vol. 10, 1996, pp. 733-736.
- Lewis, Sarah A., et al., "Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women," *J. Allergy Clin. Immunol.*, vol. 107, No. 4, Apr. 2001, pp. 615-622.
- Li, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under phase transfer catalysis," *Synthetic Communications*, vol. 32, No. 20, pp. 3081-3086, 2002.
- Linder, "Symptom scores as measurements of the severity of rhinitis," *Clinical Allergy*, 1988, vol. 18, pp. 29-37.
- Lutsky, et al., "A novel class of potent topical antiinflammatory agents: 17-benzoylated, 7α-halogeno substituted corticosteroids," *Arzneimittelforschung ("Drug Research")*, 1978, vol. 29, No. 11, pp. 1662-1667.
- Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease," *Am. J. Respir. Med.*, vol. 1, No. 4, 2002, pp. 273-282.
- Mahoney, Janette M., et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea," *Current Eye Research*, vol. 4, No. 5, 1985, pp. 531-535.
- Millard, Jeffrey W., et al., "Solubilization by cosolvents establishing useful constants for the log-linear model," *Int'l Journal of Pharmaceutics*, vol. 245, 2002, pp. 153-166.
- Mistry, Nisha, et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 16, 1997, pp. 697-705.
- Mistry, Nisha, et al., "Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 19, 1999, pp. 511-517.
- Moreno-Vargas, et al., "Synthesis and glycosidase inhibitory activities of 5-(1',4'-dideoxy-1',4'-imino-D-erythrosyl)-2-methyl-3-furoic acid (=5-[(3S,4R)-3,4-dihydroxypyrolidin-2-yl]-2-methylfuran-3-carboxylic acid) derivatives: new leads as selective alpha-L-fucosidase and beta-galactosidase inhibitors," *Helvetica Chimica Acta*, vol. 86, pp. 1894-1913, 2003.
- Nathan, et al., "A once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis," *Annals of Allergy*, 1991, vol. 67, pp. 332-338.
- Nelson, Harold S., et al., "Fluticasone propionate-salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast," *J. Allergy Clin. Immunol.*, vol. 106, No. 6, Dec. 2000, pp. 1088-1095.
- Ong, John T. H., et al., "Micellar solubilization of timobesone acetate in aqueous and aqueous propylene glycol solutions of nonionic surfactants," *Pharmaceutical Research*, vol. 5, No. 11, 1988, pp. 704-708.
- Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide," *Arch Dermatol*, vol. 125, Dec. 1989, pp. 1662-1665.
- Onrust, et al., "Mometasone furoate, a review of its intranasal use in allergic rhinitis," *Drugs*, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol. 21.
- Pettersson, Bertil, et al., "Re-evaluation of the classical mycoplasma lipophilum cluster (Weisburg, et al., 1989) and description of two new clusters in the hominis group based on 16S rDNA sequences," *Int'l Journal of Systematic & Evolutionary Microbiology*, 2001, vol. 51, pp. 633-643.
- Phillips, G. H., et al., "Synthesis and structure activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane—17B-carbothioates and—17B-carboselenoates," *Journal of Medicinal Chemistry*, 1994, vol. 37, pp. 3717-3729.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.